ArticleDrug and alcohol dependence reports2025
Prenatal cannabis screening and counseling practices by state recreational legalization status: A multi-state examination of PRAMS data (2017-2020).
Article in Drug and alcohol dependence reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Special issue: The harms and benefits of cannabis and cannabinoids in women and men and effects on their progeny.Drug and alcohol dependence reports · 2026Article
- Provider Perspectives of Conversations and Practices Surrounding Perinatal Cannabis Use.Cannabis (Albuquerque, N.M.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Despite increased recreational cannabis legalization (RCL) in the US in recent years, little is known about cannabis advice received at prenatal care visits. We aimed to examine cannabis screening and counseling occurring at prenatal care visits, including adherence of advice to current clinical guidelines and variations by RCL status. Methods: In this repeated cross-sectional study, we used 2017-2020 Pregnancy Risk Assessment Monitoring System data for 9 states to calculate weighted prevalence estimates of cannabis screening and advice received during prenatal care. We also examined adherence to the American College of Obstetricians and Gynecology's clinical guidelines for cannabis use during pregnancy, including variations across RCL and self-reported prenatal cannabis use via chi-squared tests. Results: In the sample (weighted N = 742,491), 20.53 % received cannabis advice that was adherent to clinical guidelines. Women in states with RCL more frequently reported being asked about cannabis use (78.66 % vs. 62.30 %; P < 0.001), and reported being advised against cannabis use during pregnancy (44.29 % vs. 37.06 %; P < 0.001) and lactation (31.03 % vs. 25.50 %; P < 0.001) at a prenatal care visit than women residing in states without RCL. Similarly, women in states with RCL more frequently reported being advised to use cannabis prenatally (2.96 % vs 1.45 %, P < 0.001). Women who reported any prenatal cannabis use were more likely to report being advised to use cannabis at a prenatal care visit in comparison to those who did not report prenatal cannabis use (10.10 % vs 1.16 %, P < 0.001). Conclusions: Given the variations in cannabis screening and advice occurring at prenatal care visits, findings underscore the importance of clinical practice that is consistent with current guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.